Neurotensin: Physiology and What Research Reports

Neurotensin is a short endogenous peptide, 13 amino acids long, that behaves both as a neurotransmitter or neuromodulator in the brain and as a gut hormone released from the small intestine. Since its identification, researchers have mapped it to a family of receptors and linked it to feeding behaviour, lipid handling, cardiovascular signalling, immune cell movement and tumour biology. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question. Nothing here describes a protocol for human use.

Where Neurotensin Is Produced

Two main compartments generate neurotensin. In the central nervous system it is synthesised by neurons in regions including the hypothalamus and midbrain, where it interacts with dopaminergic circuits. In the periphery it is produced by enteroendocrine N-cells of the small intestine and released in response to dietary fat. A review of neurotensin and energy balance described the peptide as acting at both central and peripheral sites to influence food intake, lipid absorption and body weight regulation (PMID 37309600).

The peptide's receptor system is conserved across species. Researchers who cloned and characterised the chicken neurotensin receptor reported its molecular structure and mapped its tissue distribution, providing comparative evidence that the receptor system is not limited to mammals (PMID 21199657).

Receptors and Signalling

Neurotensin signals through three characterised receptors. NTSR1 and NTSR2 are G protein-coupled receptors; NTSR3, also called sortilin, is a single transmembrane sorting receptor. Each has been studied in a different context.

A pharmacology study reported that neurotensin receptors regulated transactivation of the epidermal growth factor receptor (EGFR) and HER2, and that this transactivation occurred in a reactive oxygen species-dependent manner (PMID 31614143). That mechanism is one reason neurotensin appears frequently in oncology-adjacent literature: EGFR and HER2 are growth-signalling receptors of long-standing interest in cancer biology.

Metabolic and Gastrointestinal Physiology

The gut arm of neurotensin biology has drawn sustained attention. Researchers studying small intestinal epithelial cells reported that neurotensin inhibited AMPK activity while concurrently enhancing FABP1 expression, changes the authors associated with obesity and aging (PMID 40451927). AMPK is a central energy-sensing kinase and FABP1 is a fatty acid binding protein, so the finding connected neurotensin signalling directly to intestinal lipid handling.

The broader energy-balance review placed these observations in context, summarising evidence that neurotensin influences feeding, fat absorption and metabolic phenotype through both neural and enteroendocrine routes (PMID 37309600). A separate review examined potential roles of neurotensin on cognition specifically under conditions of obese-insulin resistance, bridging the metabolic and neurological literatures (PMID 30279001).

Liver and Fibrotic Signalling

Neurotensin has also been examined in hepatobiliary disease. One study reported that neurotensin contributed to cholestatic liver disease, potentially through modulation of matrix metalloprotease-7 (PMID 38522506). Matrix metalloproteases remodel extracellular matrix, which is why they recur in fibrosis research.

Cardiovascular and Cellular Effects Reported in Animal and Cell Work

A rat study investigated the impact and mechanisms of action of neurotensin on cardiac contractility in the left ventricle, reporting effects on contractile function and probing the underlying mechanism (PMID 16154127). This is isolated preclinical physiology, not a description of any therapeutic application.

At the cellular level, a review of the anti-apoptotic role of neurotensin summarised evidence that the peptide can promote cell survival signalling across several cell types (PMID 24709648). Anti-apoptotic signalling is double-edged in the literature: it is discussed as potentially protective in some tissues and as potentially permissive for tumour cell survival in others.

In neuroimmune work, researchers reported that neurotensin induced migration of human microglia and implicated neurotensin receptor-3 in that migratory response (PMID 12598608). Microglia are the resident immune cells of the central nervous system, so the finding linked a classical neuropeptide to CNS immune cell behaviour.

How Neurotensin Is Studied and Measured

Native neurotensin is degraded rapidly by peptidases, which has shaped how laboratories work with it. Three approaches dominate the literature:

• Fragment analogues. The C-terminal fragment neurotensin(8-13) retains receptor binding, and chemists have synthesised and evaluated novel multimeric neurotensin(8-13) analogues to improve receptor interaction properties (PMID 16735124).
• Radiolabelled tracers. A preclinical evaluation described a new technetium-99m labelled neurotensin analogue developed for NTSR1-targeted radionuclide imaging (PMID 39395320). Imaging agents exploit receptor density rather than attempting to change physiology.
• Receptor cloning and tissue mapping. Molecular characterisation of receptor structure and tissue distribution, as performed for the chicken neurotensin receptor, establishes where signalling can occur (PMID 21199657).

Analogues and Behavioural Pharmacology: What Studies Report

Behavioural work with stabilised analogues has documented changes over repeated administration. One study reported that repeated administration of the neurotensin analogue NT69L induced tolerance to its suppressant effect on conditioned avoidance behaviour in an animal model (PMID 11937099). Tolerance findings of this kind are important because they indicate that a single-dose effect may not persist with continued exposure.

Why Neurotensin Appears in Peptide Discussions

Readers encounter the term in several distinct contexts: as a gut hormone in obesity and metabolism research, as a dopamine-interacting neuropeptide in neuroscience, as an NTSR1 ligand used to build tumour imaging agents, and as a molecule whose anti-apoptotic signalling has been reviewed in cancer biology (PMID 24709648). Because the peptide is endogenous and short-lived, most experimental work uses analogues or fragments rather than native neurotensin.

No neurotensin peptide or analogue described in the papers above is characterised in them as an approved human therapy. The published record consists of cell studies, animal experiments, receptor characterisation and preclinical imaging evaluations. Readers researching the term should note that findings in rodents, chickens or cultured cells do not establish human outcomes, and that the same signalling property — anti-apoptotic activity, for example — is framed as favourable in one field and as a concern in another.

References

• Neurotensin and energy balance (Journal of Neurochemistry, 2023)
• The anti-apoptotic role of neurotensin (Cells, 2013)
• Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner (European Journal of Pharmacology, 2019)
• Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia (The Journal of Neuroscience, 2003)
• Potential roles of neurotensin on cognition in conditions of obese-insulin resistance (Neuropeptides, 2018)
• Preclinical evaluation of a new technetium-99m labeled neurotensin analogue for NTSR1 targeted radionuclide imaging (Bioorganic Chemistry, 2024)
• Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour (European Journal of Pharmacology, 2002)
• Molecular characterization of structure and tissue distribution of chicken neurotensin receptor (General and Comparative Endocrinology, 2011)
• Neurotensin contributes to cholestatic liver disease potentially modulating matrix metalloprotease-7 (The International Journal of Biochemistry & Cell Biology, 2024)
• Neurotensin inhibits AMPK activity and concurrently enhances FABP1 expression in small intestinal epithelial cells associated with obesity and aging (Experimental & Molecular Medicine, 2025)
• Impact and mechanisms of action of neurotensin on cardiac contractility in the rat left ventricle (European Journal of Pharmacology, 2005)
• Synthesis and evaluation of novel multimeric neurotensin(8-13) analogs (Bioorganic & Medicinal Chemistry, 2006)